Generic Name and Formulations:
Gadoxetate disodium 181.43mg/mL (0.25mmol/mL); soln for IV inj; preservative-free.
Indications for EOVIST:
For use in MRI of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.
Adults and Children:
Premature infants: not established. Give as IV bolus inj at a rate of ~2mL/sec. 0.1mL/kg (0.025mmol/kg); flush IV cannula with normal saline after inj. See full labeling re: imaging guidelines.
Nephrogenic systemic fibrosis.
Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury; avoid use. Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Elevated bilirubin (>3mg/dL) or ferritin may reduce hepatic contrast effect; perform MRI no later than 60mins following administration. Avoid extravasation. Severe renal or hepatic failure. Elderly. Pregnancy. Nursing mothers: consider interrupting nursing and pumping/discarding breast milk for up to 10hrs after inj.
Gadolinium-based contrast agent.
Serum iron using complexometric methods may result in falsely high or low values for up to 24hrs.
Nausea, headache, feeling hot, dizziness, back pain; hypersensitivity reactions.
Single-dose vials (10mL, 15mL)—5
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|